Identification of COL6A1 as the Key Gene Associated with Antivascular Endothelial Growth Factor Therapy in Glioblastoma Multiforme,Genetic Testing and Molecular Biomarkers

当前位置： X-MOL 学术 › Genet. Test. Mol. Biomark. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Identification of COL6A1 as the Key Gene Associated with Antivascular Endothelial Growth Factor Therapy in Glioblastoma Multiforme
Genetic Testing and Molecular Biomarkers ( IF 1.4 ) Pub Date : 2021-05-17 , DOI: 10.1089/gtmb.2020.0279
Han Lin _{1,

2} , Yong Yang ₁ , Chongxian Hou ₁ , Jiantao Zheng _{1,

3} , Guangzhao Lv _{1,

2} , Rui Mao _{1,

3} , Peihong Xu _{1,

2} , Shanwei Chen _{1,

2} , Yujun Zhou _{1,

4} , Peng Wang ₁ , Dong Zhou ₁

Affiliation

Background: Vascular endothelial growth factors (VEGFs) are important for glioblastoma multiforme (GBM) growth and development. However, the effects of VEGF-targeting drugs in primary GBM remain poorly understood.

中文翻译：